Cell factories for insulin production

Microbial Cell Factories

Volumn 13, Issue 1, 2014, Pages

  Baeshen, Nabih A ^a   Baeshen, Mohammed N ^a   Sheikh, Abdullah ^a   Bora, Roop S ^a   Ahmed, Mohamed Morsi M ^a,b   Ramadan, Hassan A I ^a,c   Saini, Kulvinder Singh ^a   Redwan, Elrashdy M ^a,d  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b Universities and Research centers District   (Egypt)

^c NATIONAL RESEARCH CENTRE   (Egypt)

^d GENETIC ENGINEERING AND BIOTECHNOLOGY RESEARCH INSTITUTE   (Egypt)

Author keywords

E. Coli; Expression system; Posttranslational modifications; Recombinant insulin; Transgenic plants; Yeast

Indexed keywords

INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; LONG ACTING INSULIN; PREPROINSULIN; PROINSULIN; RECOMBINANT HUMAN INSULIN; RECOMBINANT PROTEIN;

ARTICLE; CODON USAGE; ESCHERICHIA COLI; GENE EXPRESSION SYSTEM; PICHIA PASTORIS; PROTEIN PROCESSING; PROTEIN REFOLDING; SACCHAROMYCES CEREVISIAE; TRANSGENIC PLANT; BIOSYNTHESIS; GENETICS; HUMAN; METABOLISM;

ESCHERICHIA COLI; HUMANS; PLANTS, GENETICALLY MODIFIED; PROINSULIN; RECOMBINANT PROTEINS; SACCHAROMYCES CEREVISIAE;

EID: 84913599401     PISSN: None     EISSN: 14752859     Source Type: Journal    
DOI: 10.1186/s12934-014-0141-0     Document Type: Article

References (83)

1. Cohen SN, Chang ACY, Boyer HW, Helling RB: Construction of biologically functional bacterial plasmids in vitro. Proc Natl Acad Sci U S A 1973, 70:3240-3244.
2. Nielsen J: Production of biopharmaceutical proteins by yeast. Landes Biosci Bioengineered 2013, 4(4):207-211.
3. Goodman M, Market watch: Sales of biologics to show robust growth through to 2013. Nat Rev Drug Discov 2009, 8:837.
4. Aggarwal S: What's fueling the biotech engine 2010 to 2011. Nat Biotechnol 2011, 29:1083-1089.
5. Walsh G: Biopharmaceuticals: approvals and approval trends in 2004. Biopharm Int 2005, 18:58-65.
6. Walsh G: Biopharmaceuticals: approval trends in 2005. BioPharm Int 2006, 9:58-68.
7. Walsh G: Biopharmaceuticals: approval trends in 2006. BioPharm Int 2007, 20:40-48.
8. Walsh G: Biopharmaceuticals: approval trends in 2007. BioPharm Int 2008, 21:52-65.
9. Walsh G: Biopharmaceuticals: approval trends in 2008. BioPharm Int 2009, 22(10):68-77.
10. Walsh G: Biopharmacetiucal approval trends in 2009. BioPharm Int 2010, 23(10):30-41.
11. Walsh G: Biopharmaceutical benchmarks. Nat Biotechnol 2010, 28:917-924.
12. Walsh G: New biopharmaceuticals. BioPharm Int 2012, 25:34-36.
13. Walsh G: Biopharmaceuticals approval trends in 2013. Biopharm Int 2013, 26(4):54-56.
14. Walsh G: Therapeutic insulins and their large-scale manufacture. Appl Microbiol Biotechnol 2005, 67:151-159.
15. Ferrer-Miralles N, Domingo-Espin J, Corchero JL, Vazquez E, Villaverde A: Microbial factories for recombinant pharmaceuticals. Microb Cell Fact 2009, 8:17.
16. Nilsson J, Jonasson P, Samuelsson E, Stahl S, Uhlen M: Integrated production of human insulin and its C-peptide. J Biotechnol 1996, 48:241-250.
17. Thim L, Hansen MT, Norris K, Hoegh I, Boel E, Forstrom J, Ammerer G, Fiil NP: Secretion and processing of insulin precursors in yeast. Proc Natl Acad Sci U S A 1986, 83:6766-6770.
18. Markussen J, Damgaard U, Diers I, Fiil N, Hansen MT, Larsen P, Norris F, Norris K, Schou O, Snel L, Thim L, Voigt HO: Biosynthesis of human insulin in yeast via single chain precursors. Diabetologia 1986, 29:568A-569A.
19. Kjeldsen T: Yeast secretory expression of insulin precursors. Appl Microbiol Biotechnol 2000, 54:277-286.
20. Hollenberg CP, Gellissen G: Production of recombinant proteins by methylotrophic yeasts. Curr Opin Biotechnol 1997, 8:554-560.
21. Gellissen G, Hollenberg CP, Application of yeasts in gene expression studies: A comparison of Saccharomyces cerevisiae, Hansenula polymorpha and Kluyveromyces lactis - a review. Gene 1997, 190:87-97.
22. Romanos M: Advances in the use of Pichia pastoris for high-level gene expression. Curr Opin Biotechnol 1995, 6:527-533.
23. Weydemann U, Keup P, Piontek M, Strasser AW, Schweden J, Gellissen G, Janowicz ZA: High-level secretion of hirudin by Hansenula polymorpha -authentic processing of three different preprohirudins. Appl Microbiol Biotechnol 1995, 44:377-385.
24. Porro D, Sauer M, Branduardi P, Mattanovich D: Recombinant protein production in yeasts. Mol Biotechnol 2005, 31:245-259.
25. Yanagita M, Nakayama K, Takeuchi T: Processing of mutated proinsulin with tetrabasic cleavage sites to bioactive insulin in the non-endocrine cell line, COS-7. FEBS Lett 1992, 311:55-59.
26. Arakawa T, Yu J, Chong DKX, Hough J, Engen PC, Langridge WHR: A plant - based cholera toxin B subunit-insulin fusion protein protects against the development of autoimmune diabetes. Nat Biotechnol 1998, 16:934-938.
27. Nykiforuk CL, Boothe JG, Murray EW, Keon RG, Goren HJ, Markley NA, Moloney MM: Transgenic expression and recovery of biologically active recombinant human insulin from Arabidopsis thaliana seeds. Plant Biotech J 2006, 4:77-85.
28. Boyhan D, Daniell H: Low-cost production of proinsulin in tobacco and lettuce chloroplasts for injectable or oral delivery of functional insulin and C-peptide. Plant Biotech J 2011, 9:585-598.
29. Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
30. Sahdev S, Khattar SK, Saini KS: Production of active eukaryotic proteins through bacterial expression systems: a review of the existing biotechnology strategies. Mol Cell Biochem 2008, 307:249-264.
31. Arya R, Bhattacharya A, Saini KS: Dictyostelium discoideum-a promising expression system for the production of eukaryotic proteins. FASEB J 2008, 22:4055-4066.
32. Ferrer-Miralles N, Villaverde A: Bacterial cell factories for recombinant protein production; expanding the catalogue. Microb Cell Fact 2013, 12:113.
33. Kjeldsen T, Pettersson AF, Hach M: Secretory expression and characterization of insulin in Pichia pastoris. Biotechnol Appl Biochem 1999, 29:79-86.
34. Gerngross TU: Advances in the production of human therapeutic proteins in yeasts and filamentous fungi. Nat Biotechnol 2004, 22:1409-1414.
35. Mansur M, Cabello C, Hernandez L, Pais J, Varas L, Valdes J, Terrero Y, Hidalgo A, Plana L, Besada V, Garcia L, Lamazares E, Castellanos L, Martinez E: Multiple gene copy number enhances insulin precursor secretion in the yeast Pichia pastoris. Biotechnol Lett 2005, 27:339-345.
36. Wurm FM: Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 2004, 22:1358-1393.
37. Vajo Z, Fawcett J, Duckworth WC: Recombinant DNA technology in the treatment of diabetes: insulin analogs. Endocr Rev 2001, 22:706-717.
38. Ahmad B: Pharmacology of insulin. Br J Diabetes Vasc Dis 2004, 4:10-14.
39. Jenkins N: Modifications of therapeutic proteins: challenges and prospects. Cytotechnology 2007, 53:121-125.
40. Walsh G, Jefferis R: Post-translational modifications in the context of therapeutic proteins. Nat Biotechnol 2006, 24:1241-1252.
41. Wacker M, Linton D, Hitchen PG, Nita-Lazar M, Haslam SM, North SJ, Panico M, Morris HR, Dell A, Wren BW, Aebi M: N-linked glycosylation in Campylobacter jejuni and its functional transfer into E. coli. Science 2002, 298:1790-1793.
42. Feldman MF, Wacker M, Hernandez M, Hitchen PG, Marolda CL, Kowarik M, Morris HR, Dell A, Valvano MA, Aebi M: Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia coli. Proc Natl Acad Sci U S A 2005, 102:3016-3021.
43. Wacker M, Feldman MF, Callewaert N, Kowarik M, Clarke BR, Pohl NL, Hernandez M, Vines ED, ValvanoMA, Whitfield C, AebiM: Substrate specificity of bacterial oligosaccharyltransferase suggests a common transfer mechanism for the bacterial and eukaryotic systems. Proc Natl Acad Sci U S A 2006, 103:7088-7093.
44. Fisher AC, Haitjema CH, Guarino C, Celik E, Endicott CE, Reading CA, Merritt JH, Ptak AC, Zhang S, DeLisa MP: Production of secretory and extracellular N-Linked glycoproteins in Escherichia coli. Appl Environ Microbiol 2011, 77:871-881.
45. Ihssen J, Kowarik M, Dilettoso S, Tanner C, Wacker M, Thoxy-Meyer L: Production of glycoprotein vaccines in Escherichia coli. Microb Cell Fact 2010, 9:61.
46. Lizak C, Fan Y, Web TC, Aebi M: N-Linked glycosylation of antibody fragments in Escherichia coli. Bioconjug Chem 2011, 22:488-496.
47. Pandhal H, Ow SY, Noirel J, Wright PC: Improving N-glycosylation efficiency in Escherichia coli using shotgun proteomics metabolic network analysis, and selective reaction monitoring. Biotechnol Bioeng 2011, 108:902-912.
48. Chen R: Bacterial expression systems for recombinant protein production: E. coli and beyond. Biotechnol Adv 2012, 30:1102-1107.
49. Makrides SC: Strategies for achieving high-level expression of genes in Escherichia coli. Microbiol Rev 1996, 60:512-538.
50. Kane JF: Effects of rare codon clusters on high-level expression of heterologous proteins in Escherichia coli. Curr Opin Biotechnol 1995, 6(5):494-500.
51. Trundova M, Celer V: Expression of porcine circovirus 2 ORF2 gene rquires codon optimized E.coli cells. Virus Genes 2007, 34:199-204.
52. Sorensen HP, Sperling-Petersen HU, Mortensen KK: Production of recombinant thermostable proteins expressed in Escherichia coli: completion of protein synthesis is the bottleneck. J Chromatogr B Analyt Technol Biomed Life Sci 2003, 786:207-214.
53. Bill RM, Henderson PJF, Iwata S, Kunji ERS, Michel H, Neutze R, Newstead S, Poolman B, Tate CG, Voge H: Overcoming barriers to membrane protein structure determination. Nat Biotechnol 2011, 29(4):335-340.
54. Huang CJ, Lin H, Yang X: Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements. J Ind Microbiol Biotechnol 2012, 39:383-399.
55. Reilly DE, Yansura DG: Production of monoclonal antibodies in E. coli. In Current Trends in Monoclonal Antibodies Development and Manufacturing. Edited by Shire SJ, Gombotz W, Bechtold-Peters K, Andya J. New York: Springer; 2010:295-308.
56. Overton TW: Recombinant protein production in bacterial hosts. Drug Discov Today 2014, 19(5):590-601.
57. Carrio MM, Villaverde A: Role of molecular chaperones in inclusion body formation. Febs Lett 2003, 537(1-3):215-221.
58. De Marco A: Protocol for preparing proteins with improved solubility by co-expressing with molecular chaperones in Escherichia coli. Nat Protoc 2007, 2(10):2632-2639.
59. Chance R, Frank B: Research, development production and safety of biosynthetic human insulin. Diabetes Care 1993, 16(3):133-142.
60. Chance R, Glazer N, Wishner K: Insulin Lispro (Humalog). In Biopharmaceuticals, an Industrial Perspective. Edited by Walsh G, Murphy B. Kluwer: Dordrecht; 1999:149-172.
61. Blundell T, Dodson G, Hodgkin D, Mercola D: Insulin: the structure in the crystal and its reflection in chemistry and biology. Adv Prot Chem 1972, 26:279-402.
62. Kang S, Creagh F, Peters J, Brange J, Volund A, Owens D: Comparison of subcutaneous soluble human insulin and insulin analogues on meal-related plasma glucose excursions in type-1 diabetic subjects. Diabetes Care 1991, 14:571-577.
63. Brange J, Ribel J, Hansen JF, Dodson G, Hansen MT, Havelund S, Melberg SG, Norris K, Norris L, Snel L, Sorensen AR, Voigt HO: Monomeric insulins obtained by protein engineering and their medical implications. Nature 1988, 333:679-682.
64. Brange J, Owens DR, Kang S, Volund A: Monomeric insulins and their experimental and clinical implications. Diabetes Care 1990, 13(9):923-954.
65. Wildt S, Gerngross TU: The humanization of N-glycosylation pathways in yeast. Nat Microbiol 2005, 3:119-128.
66. Grinna LS, Tschopp JF: Size distribution and general structural features of N-linked oligosaccharides from the methylotrophic yeast, Pichia pastoris. Yeast 1989, 5:107-115.
67. Tschopp JF, Sverlow G, Kosson R, Craig W, Grinna L: High level secretion of glycosylated invertase in the methylotrophic yeast pichia pastoris. Biotechnology 1987, 5:1305-1308.
68. Ellis SB, Brust PF, Koutz PJ, Waters AF, Harpold MM, Gingeras TR: Isolation of alcohol oxidase and two other methanol regulatable genes from the yeast Pichia pastoris. Mol Cell Biol 1985, 5:1111-1121.
69. Tschopp JF, Brust PF, Cregg JM, Stillman C, Gingeras TR: Expression of the lacZ gene from two methanol regulated promoters in Pichia pastoris. Nucleic Acids Res 1987, 15:3859-3876.
70. Porro D, Gasser B, Fossati T, Maurer M, Branduardi P, Sauer M, Mattanovich D: Production of recombinant proteins and metabolites in yeasts. Appl Microbiol Biotechnol 2011, 89:939-948.
71. Shin CS, Hong MS, Bae CS, Lee J: Enhanced production of human miniproinsulin in fed-batch cultures at high cell density of Escherichia coli BL21(DE3)[pET-3aT2M2]. Biotechnol Prog 1997, 13:249-257.
72. Mergulhao F, Taipa M, Cabral J, Monteiro G: Evaluation of bottlenecks in proinsulin secretion by Escherichia coli. J Biotechnol 2004, 109:31-43.
73. Gurramkonda C, Polez S, Skoko N, Adnan A, Gabel T, Chugh D, Swaminathan S, Khanna N, Tisminetzky S, Rinas U: Application of simple fed-batch technique to high-level secretory production of insulin precursor using Pichia pastoris with subsequent purification and conversion to human insulin. Microb Cell Fact 2010, 9:31.
74. Owens DR, Vora JP, Dolben J: Human insulin and beyond: semisynthesis and recombinant DNA technology reviewed. In Biotechnology of Insulin Therapy. Edited by Pickup JC. Oxford: Blackwell; 1991:24-41.
75. Frank B: Manupilation of the position of proline in the B chain produced monomeric insulins. Diabetes 1991, 40(Suppl 1):423A.
76. Kurtzhals P, Havelund S, Jonassen S, Markussen J: Effect of fatty acids and selected drugs on the albumin binding of a long acting, acylated insulin analogue. J Pharm Sci 1997, 86(12):1365-1368.
77. Owens DR, Zinman B, Bolli G: Insulins today and beyond. Lancet 2001, 358:739-746.
78. Havelund S, Plum A, Ribel U, Jonassen I, Volund A, Markussen J, Kurtzhals P: The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res 2004, 21(8):1498-1504.
79. Hou J, Tyo KEJ, Liu Z, Petranovic D, Nielsen J: Metabolic engineering of recombinant protein secretion by Saccharomyces cerevisiae. FEMS Yeast Res 2012, 12:491-510.
80. Kjeldsen T, Hach M, Balschmidt P, Havelund S, Pettersson AF, Markussen J: Prepro-leaders lacking N-linked glycosylation for secretory expression in the yeast Saccharomyces cerevisiae. Protein Expr Purif 1998, 14:309-316.
81. Staub JM, Garcia B, Graves J, Hajdukiewicz PT, Hunter P, Nehra N, Paradkar V, Schlittler M, Carroll JA, Spatola L, Ward D, Ye G, Russell DA: High-yield production of a human therapeutic protein in tobacco chloroplasts. Nat Biotechnol 2000, 18:333-338.
82. Van Rooijen GJH, Moloney MM: Plant seed oil-bodies as carriers for foreign proteins. BioTechnology 1995, 13:72-77.
83. Deckers H, Moloney MM, Baum A: The case for recombinant production of pharmaceutical proteins in plants. Annu Rep Med Chem 1999, 34:237-245.